clinical trial · NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Haematological MalignancyAcute Myeloid LeukemiaNon Hodgkin LymphomaMultiple MyelomaHigher-risk Myelodysplastic SyndromePeripheral T Cell LymphomaCCS1477PomalidomideDexamethasoneAzacitidineVenetoclaxBortezomibIxazomibElranatamab
brief summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
started
Aug 9, 2019
primary completion
Mar 31, 2027
completion
Mar 31, 2027
last updated
Dec 18, 2025
detailed description
This includes patients with Peripheral T-cell lymphoma.
official title
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol